Results 20,901-20,920 of 32,978 for speaker:Catherine Connolly
- Public Accounts Committee: Business of Committee (8 Nov 2018)
Catherine Connolly: There are two matters. The first is the adequacy of the internal audit resources, which is a practical matter. Without adequate internal audit resources, we are going nowhere. Separate to that is the information technology programme.
- Public Accounts Committee: Business of Committee (8 Nov 2018)
Catherine Connolly: That is absolutely key.
- Public Accounts Committee: Business of Committee (8 Nov 2018)
Catherine Connolly: There are governance issues we saw that are clearly the direct responsibility of the board and the people on it. In fairness to ETBs, this is a matter of a lack of resources for internal audit.
- Public Accounts Committee: Business of Committee (8 Nov 2018)
Catherine Connolly: We have all been informed about the delay in rolling out information technology. They are struggling on that level. I am the first to be critical about a lack of governance but these matters are beyond the ETBs currently, in fairness to them.
- Public Accounts Committee: Business of Committee (8 Nov 2018)
Catherine Connolly: In the course of that the Office of Public Works indicated it was looking at Galway. One of the five elements related to Galway. It was Fairgreen.
- Public Accounts Committee: Business of Committee (8 Nov 2018)
Catherine Connolly: That is fine. We can come back to it as it will be on the correspondence next week.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: While I would like to go into the minutiae, that is not the job of the committee. Our job is to examine governance, accountability and value for money. In that context, what is the cost of running the cervical smear service every year?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Would I be wrong in saying it is €22 million or €23 million per year?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Was that €32 million?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Is that clearly set out? I had difficulty finding that figure, although I must have got it somewhere.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I came without the accounts, but if I look at them will I see a figure for €32 million?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: What will the failure in governance and open disclosure cost? What is the estimate?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I am talking about everything, the investigation, the Scally report, the ongoing Royal College of Surgeons report, etc.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: One moment, please. There is a figure for the running of it. The figure for rectifying it is entirely separate. What is the cost of the failure of governance and open disclosure? There must be some figure.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Mr. Breen might answer that.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Would I be totally wrong to say the difficulties will the service will cost more than running it? Would I be far off the mark?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Will Mr. Breen help me with that? Would I be way off the mark to say the total cost of the cases, awards, legal fees and various investigations will be higher than the €32.1 million it cost to run the service in 2017?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I understand.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Would anyone have a bald figure on what that cost will be? It is clearly more than €32.1 million. Does anyone have an idea of what the cost will be, separate from the cost of rectifying and the new contracts?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I understand that.